{"id":"W4365503784","doi":"10.1200/jco.22.02152","title":"Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Genentech; PharmaMar; Eisai; Fujirebio US; Puma Biotechnology; Incyte; Clovis Oncology; Karyopharm Therapeutics; Gilead Sciences; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Lenvatinib; Clinical endpoint; Internal medicine; Endometrial cancer; Oncology; Phases of clinical research; Randomized controlled trial; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00711297,0.0003262823,0.004954542,0.0003979656,0.0001046937,0.00002341265,0.0003112097,0.0003658025,0.0004488976],"category_scores_gemma":[0.01853409,0.0001751903,0.0006637396,0.001707405,0.0003464263,0.0001354041,0.0001377395,0.00133013,0.00001742484],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004242216,"about_ca_system_score_gemma":0.001432211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001148476,"about_ca_topic_score_gemma":0.000599105,"domain_scores_codex":[0.9911995,0.002694961,0.004496321,0.0004582243,0.0006875651,0.0004634073],"domain_scores_gemma":[0.969588,0.0271279,0.002141728,0.0003293423,0.0003372773,0.0004757539],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7337061,0.003657205,0.01362836,0.000009207606,0.001718394,0.0008669796,0.0005141866,0.0000659858,0.00004801912,0.000008225345,0.0004804054,0.245297],"study_design_scores_gemma":[0.8546623,0.01614877,0.1206267,0.000156725,0.002134258,0.00002908568,0.0003222917,0.0002029418,0.00003184922,0.0001237487,0.005419761,0.0001415795],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864234,0.002752746,0.0000190413,0.005469279,0.001657505,0.003081915,0.00003819748,0.00004292508,0.0005149344],"genre_scores_gemma":[0.9838013,0.0131851,0.0001284074,0.0009073522,0.001568953,0.0001027357,0.00004986212,0.00003267352,0.0002236191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2451554,"threshold_uncertainty_score":0.9897332,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1125811469560184,"score_gpt":0.4825073820538253,"score_spread":0.369926235097807,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}